Kornimate/medical-research-clean huggingface dataset:
psychopharmacotherapy for depressive patients

Conditions: Major Depressive Disorder

Summary: the primary purpose of this study is to compare the short (12 week) and long-term (1-year) efficacy and the tolerability between stepwise psychopharmacotherapy and antidepressant monotherapy for 12 weeks in adult patients with major depressive disorders, stratified by the multimodal serum biomarker scores.

this is prospective randomized controlled trials (rct) to evaluate clinical impact of antidepressant monotherapy vs stepwise psychopharmacotherapy in patients with major depressive disorders, stratified by multimodal serum biomarker scores. participants will be predicted treatment response based on the multimodal serum biomarker scores at baseline, will be categorized into good and poor treatment responders and then randomly assigned to two groups: stepwise pharmacotherapy group and antidepressant monotherapy group. the hypothesis is that in the good treatment responder, the depression remission will be achieved irrespective of treatment modality (stepwise pharmacotherapy or antidepressant monotherapy) group while in poor treatment responders, the treatment response of stepwise pharmacotherapy will be superior to those of antidepressant monotherapy.

Eligibility criteria:
inclusion criteria: * 19 to 65 years * diagnostic and statistical manual of mental disorders-iv criteria for major depressive disorder by study psychiatrists * score≥17 on hamilton depression rating scale-17 * with ability to understand the objective of the study and sign informed consent * initiation of an antidepressant treatment for the current episode or no psychotropics excluding sleep pills or benzodiazepines within 1 month of participation exclusion criteria: * current or lifetime diagnosis of bipolar disorder, schizophrenia, schizoaffective disorder, schizophreniform disorder, psychotic disorder not otherwise specified, or other psychotic disorders * current major depressive disorder with psychotic features * history of organic psychosis, epilepsy, or seizure disorder * current anorexia nervosa or obsessive compulsive disorder * unstable or uncontrolled medical condition * unable to complete the psychiatric assessment or comply with the medication regimen due to a severe physical illness * history of anticonvulsant treatment * electroconvulsive therapy for the current depressive episode * hospitalization for any psychiatric diagnosis except depressive disorder (e.g., alcohol/drug dependence) * severly high risk of suicide, self-harm or homicide by investigator's assessment * pregnant or breastfeeding * lack of treatment information on the current depressive episode

Keywords: depression antidepressant monotherapy stepwise psychopharmacotherapy multimodal serum biomarker score
interactive oral health educational program for children with intellectual disability and their caregivers

Conditions: Intellectual Disability; Caregiver Burden

Summary: conducting a research with an interactive oral health educational program and assessing knowledge of caregivers using a questionnaire will help in collecting information about the oral health educational program for children with intellectual disability and the extent of knowledge of care givers in egypt. this will aid in identifying the knowledge gap, interest, attitude, and practice challenges regarding the children with intellectual disability.

for all children, oral health is a crucial component of overall health, but it is even more crucial for kids with particular medical requirements. despite the high prevalence of dental disorders among them, people with disabilities or illnesses receive less oral treatment than the general population. according to reports, the largest unmet health need among disabled individuals is dental care. the general health and well-being of the body are closely linked to oral health. the quality of life is enhanced by good dental health. mentally disabled patients have worse oral health than their normal counterparts, which makes it harder for them to use the oral cavity for activities like eating, swallowing, speaking, chewing, and drooling. this leads to malocclusion, compromised appearance, and poor overall health. educating parents, guardians, and other caregivers on the causes and self-care prevention of dental disease is a critical part in lowering the caries/gingivitis rate among these children globally. because of the insufficiency of oral health programs offered in institutions or schools for these particular children, parents and care givers usually have little knowledge about mouth health. they do not understand the significance of dental health, and the educational resources that are accessible to them are frequently insufficient and out-of-date

Eligibility criteria:
inclusion criteria: * children with intellectual disability * care givers * iq(mild)50-69 * iq(moderate) 35-49 exclusion criteria: * iq(severe) 20-34 * refusal to get enrolled in the study.

Keywords: interactive oral health educational program
bromfenac sodium hydrate eye drops in familial exudative vitreoretinopathy

Conditions: Familial Exudative Vitreoretinopathies

Summary: this study aims to investigate the efficacy and safety of bromfenac sodium hydrate eye drops in patients with familial exudative vitreoretinopathy receiving diode laser photocoagulation.

this study aims to evaluate the presence of macular edema as the primary measure and the presence of conjunctival injection as the secondary measure for the investigation of the efficacy of bromfenac sodium hydrate eye drops in patients with familial exudative vitreoretinopathy receiving diode laser photocoagulation.

Eligibility criteria:
inclusion criteria: * newly diagnosed patients with familial exudative vitreoretinopathy * needing diode laser photocoagulation * consent to the study exclusion criteria: * history of corneal diseases * history of hypersensitivity to bromfenac sodium * history of hypersensitivity to non-steroidal anti-inflammatory drugs * progressive ocular infection * liver diseases * hypersensitivity to sulfur dioxide * receiving anti-coagulation drugs * history of coagulopathies
clinical study of venetoclax combined with cacag regimen in the treatment of newly diagnosed acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: the purpose of this study is to compare the efficacy and safety of venetoclax combined with cacag regimen with the traditional "3+7" regimen in the treatment of newly diagnosed acute myeloid leukemia.

despite the availability of hematopoietic stem cell transplantation and the emergence of many new therapeutic drugs, the prognosis of newly diagnosed acute myeloid leukemia is still poor.over the past years, combination chemotherapy with anthracycline and standard dose cytarabine (standard "3+7" induction therapy) remains the standard induction. in order to improve the outcome of patients with de novo aml, we developed a venetoclax combined with cacag regimen in the treatment of de novo aml. in this study, we intent to compare the efficacy and safety of venetoclax combined with cacag regimen with the traditional "3+7" regimen in the treatment of newly diagnosed acute myeloid leukemia.

Eligibility criteria:
inclusion criteria: patients who are able to understand and willing to sign the informed consent form (icf). * all patients should aged 14 to75 years,no gender limitation. * patients who are newly diagnosed with aml(no m3). * liver function: alt and ast≤2.5 times the upper limit of normal ,bilirubin≤2 times the upper limit of normal; * renal function: creatinine ≤the upper limit of normal; * patients without any uncontrolled infections , without organ dysfunction or without severe mental illness; * the score of eastern cooperative oncology group (ecog) is 0-3,and the predicted survival ≥ 4 months. * patients without severe allergic constitution. exclusion criteria: * patients with allergy or contraindication to the study drug; * female patients who are pregnant or breast-feeding. * patients with a known history of alcohol or drug addiction on the basis that there could be a higher risk of non-compliance to study treatment; * patients with mental illness or other states unable to comply with the protocol; * less than 6 weeks after surgical operation of important organs. * liver function: alt and ast\>2.5 times the upper limit of normal ,bilirubin\> 2 times the upper limit of normal;renal function: creatinine \>the upper limit of normal; * the patient is not suitable for this clinical trial (poor compliance, substance abuse, etc.)

Keywords: acute myeloid leukemia first line therapy
low-molecular-weight heparin (lmwh) for deep venous thrombosis (dvt) prophylaxis

Conditions: Deep Venous Thrombosis

Summary: 1. the use of lmwh following open reduction and internal fixation of ankle fractures will reduce the number of thrombi formed. 2. the rates of clinically significant dvt will be equivalent between two groups.

routine use of thromboprophylaxis may be over treatment and definitely increases healthcare costs. while prophylaxis may reduce the number of thrombi formed the exact number and clinical significance of these is unknown. this study seeks to answer the question of whether or not dvt prophylaxis with low-molecular-weight heparin (lmwh) following orif of ankle fractures is warranted.

Eligibility criteria:
inclusion criteria: * at least 18 years old * surgical ankle fracture able to be definitively treated with one operation exclusion criteria: * younger than 18 years of age * other significant injury * known hypercoagulable state * history of bleeding disorder * history of dvt

Keywords: low-molecular-weight-heparin open reduction and internal fixation thromboprophylaxis
a prospective clinical study on the safety and efficacy of radiofrequency ablation for the treatment of patients with desmoid tumors

Conditions: Desmoid Tumor; Desmoid Fibromatosis; Desmoid

Summary: this is a prospective study on the safety and effectiveness of radiofrequency ablation in patients with desmoid tumors. in the study group, all patients after radiofrequency ablation of the tumor after 1 month will be evaluated using mri and ct studies and, if solid components of the tumor are detected, repeated surgical treatment is performed followed by active monitoring after 1 month. in the absence of a solid component, the effect is estimated by the volume of the necrotic process and monitored in dynamics every 3 months.


Eligibility criteria:
inclusion criteria: 1. patients with histologically verified diagnosis of dermoid tumor 2. the presence of progressive, symptomatic or functionally significant df. 3. written informed consent to participate in the study 4. age from 18 to 75 years 5. the functional status of the patient according to the ecog 0-2 scale 6. normal renal function (estimated creatinine clearance 60 ml/min); 7. normal level of bilirubin and liver enzymes (ast, alt - no more than 3 norms); 8. left ventricular ejection fraction \&gt; 55% 9. satisfactory bone marrow function (hemoglobin level 9 g/dl, neutrophil count 1.5 thousand/ml, platelet count \&lt; 100 thousand/ml); exclusion criteria: 1. the inability to obtain informed consent to participate in the study 2. synchronous or metachronous cancer 3. clinically significant diseases of the cardiovascular system 4. clinically significant cns diseases 5. previous grade 2 polyneuropathy and above 6. current infection or other severe or systemic disease that increases the risk of complications of therapy 7. pregnancy, lactation
functional and radiographic outcomes of hallux valgus correction by mini-invasive surgery with reverdin-isham percutaneous osteotomy

Conditions: Hallux Valgus

Summary: minimally invasive surgery (mis) represents one of the most innovative surgical treatments of hallux valgus (hv). however, long-term outcomes still remain a matter of discussion within the orthopaedic community. the purpose of this longitudinal prospective study was to evaluate radiographic and functional outcomes in patients with mild-to-severe hv who underwent reverdin-isham and akin percutaneous osteotomy, following exostosectomy and lateral release.

one hundred and eighty patients with mild-to-severe symptomatic hv were treated by mis. clinical evaluation was assessed pre-operatively, as well as at 3 and 12 months after surgery and at final follow-up of 48 months, using the american orthopaedic foot and ankle society (aofas) hallux grading system. patient satisfaction and complications were recorded.further parameters assessed were postoperative pain at rest and during movement by the numerical rating scale (nrs), patient satisfaction using the visual analogue scale (vas), quality of life, and return to daily activities. incidence of chronic pain syndrome (cps), type of anesthesia and asa were evaluated and recorded. computer-assisted measurement of antero-posterior radiographs was taken pre-operatively, as well as at 3 and 12 months after surgery and at 48-month follow-up, analysing the intermetatarsal angle (ima), the hallux valgus angle (hva), the distal metatarsal articular angle (dmaa), and the tibial sesamoid position. also, the bridging bone/callus formation was evaluated at the different radiographic follow-ups, while the articular surface congruency and the metatarsal index were calculated only preoperatively and at last follow-up. statistical analysis was carried out using the paired t-test. statistical significance was set at p \< 0.05.

Eligibility criteria:
inclusion criteria: * patients with mild to severe symptomatic hallux valgus exclusion criteria: * congenital deformities of the foot * hallux rigidus * previous first ray trauma or foot and ankle surgery * rheumatic, dismetabolic, neurologic, infective, or psychiatric pathologies.

Keywords: hallux valgus reverdin-isham osteotomy minimally invasive surgery percutaneous distal osteotomy first ray forefoot
exploratory cognition study of sertindole in patients with schizophrenia

Conditions: Schizophrenia

Summary: the purpose of this exploratory study is to evaluate the effects of sertindole and olanzapine on neurocognitive functioning in patients with schizophrenia.

cognitive deficits, including impairments in areas such as memory, attention, and executive function, are major determinants and predictors of long-term disability in schizophrenia. at present, available antipsychotic medications are relatively ineffective in improving cognition. however, scientific discoveries during the past decade suggest that it may be possible to develop medications that are effective in improving cognition in schizophrenia. one of the important reasons to focus on cognitive deficits as a target for pharmacological treatment, is the association found between cognitive impairment and social dysfunction observed in patients with schizophrenia. pervasive cognitive deficits have a limiting effect on the quality of life of patients with schizophrenia including social interaction and problem solving, community living, and employment prospects.

Eligibility criteria:
inclusion criteria: * patients with schizophrenia * participation in 11286 study * capable of completing all study-related psychometric activities for the duration of the study

Keywords: schizophrenia
efficacy and tolerability of prednisolone acetate 0.5% cream versus betamethasone valerate 0.1% cream in cortisosensitive dermatosis

Conditions: Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis

Summary: topical corticosteroids are largely used in dermatology. the major problem related to their use is that the same mechanisms underlying their therapeutic effects (antiinflammatory and antiproliferative) may lead to adverse events. conditions sensitive to corticosteroids require formulations with mild to moderate potency while high-potency corticosteroids era required in less responsive conditions. the aim of the present study is to compare the safety and efficacy of prednisolone acetate 0.5% cream (mild-potency non-fluoridated corticosteroid) versus betamethasone valerate 0.1% cream (high-potency fluoridated corticosteroid) in the treatment of mild to moderate cortisosensitive dermatosis (atopic dermatitis, contact dermatitis, seborrheic dermatitis and psoriasis). the study hypothesis is that 0.5% prednisolone cream will be as effective as 0.1% betamethasone cream and will be an alternative option to treat corticosensitive dermatosis in body areas where the use of fluoridated corticosteroids is contraindicated, such as the face.


Eligibility criteria:
inclusion criteria: * subjects with corticosensitive dermatosis (atopic dermatitis, contact dermatitis, seborrheic dermatitis, psoriasis) mild to moderate in intensity; * compliance of the subject to the treatment protocol; * agreement with the terms o the informed consent by the participants * subjects who did not use the following medicines before inclusion: topical corticosteroids or other therapies to dermatitis (30 days); oral corticosteroids (180 days); parenteral corticosteroids (180 days); immunomodulators/immunosuppressor (30 days); any drug under investigation (1 year); any therapy for the studied clinical conditions (180 days); keratolytic agents (30 days); emollient agents (30 days); tazarotene (30 days); vitamin d (topical or oral, 30 days); methotrexate (30 days); acitretin (2 years); uv light (30 days); puva therapy (30 days). exclusion criteria: * pregnancy or risk of pregnancy * lactation * history of allergy of any component of the formulations * other conditions considered by the investigator as reasonable for non-eligibility * hiv positivity * drug abuse * subjects without previous response to topical corticosteroids * subjects with intense sun exposure within 15 days of the screening

Keywords: prednisolone acetate betamethasone valerate
westlake personalized nutrition and health cohort for drug addicts

Conditions: Drug Addiction; Undernutrition; Drug Abuse

Summary: this is a prospective cohort study of drug addicts confined in zhejiang rehabilitation centers. the primary aim of this study is to investigate the association between diet and health status among drug addicts. the second aim is to characterize the continuous blood glucose response to dietary intakes over 2 weeks. the third aim is to describe the dynamic changes of gut microbiota at three time points in drug addicts during compulsory detoxification and to evaluate the association between gut microbiota, diet and addiction severity.

over recent decades, there is a growing trend of drug addiction in china that poses great public health challenges. drug abuse can lead to many health related problems such as malnutrition and mental disorders along with reduced quality of life. dietary intervention plays a pivotal role in disease prevention and drug rehabilitation for drug addicts, but the associations between dietary intake and health related outcomes among drug addicts remain unclear. in addition, the relationship between the human gut microbiota and its response to addictive drugs as a newly arisen subject is given wide attention in recent years. however, the underlying mechanism requires further investigation. the dynamic changes of gut microbiota among drug addicts during compulsory drug rehabilitation period are in vague. under the same diet exposure, different drug addicts may have different blood glucose responses as well as gut microbiota profiles. therefore, in order to examine the association between diet, gut microbiota and drug addiction, our study design will include three components: (1) the measurement of dietary intake using ffq while the menu offered by drug rehabilitation center and food diary; (2) the measurements of blood glucose over 2 weeks using continuous glucose monitors; and (3) the measurements of gut microbiota at three time points using 16s rrna sequencing techniques.

Eligibility criteria:
inclusion criteria: * drug addicts aged between 18 yrs and 65yrs. * drug addicts lived in zhejiang drug rehabilitation centers. * drug addicts who have stayed in drug rehabilitation center for no more than 6 months. exclusion criteria: * drug addicts diagnosed with cancer or other serious physical and mental disorders.

Keywords: personalized nutrition drug addicts gut microbiota
the safety and scientific validity of low-dose whole brain radiotherapy in alzheimer's disease.

Conditions: Alzheimer Disease

Summary: alzheimer's disease is the most frequent neurocognitive disorder associated with dementia, with a constantly increasing prevalence associated with an aging population. amyloid deposition is considered as the first molecular event on the onset of alzheimer's disease. it has already been demonstrated that low-dose radiotherapy is capable of reducing alzheimer's disease-associated amyloid-β plaques and improving cognitive function in an animal model. in human, low-dose radiotherapy has demonstrated effectiveness in reducing bronchial amyloidosis. the present study aims to conduct research by including 10 patients with a diagnosis of mild or moderately severe alzheimer's disease and with evidence of amyloid pathology. furthermore, the aim is to demonstrate the effectiveness of low-dose radiotherapy in reducing amyloid deposits in the human brain using molecular imaging (flutemetamol(18f) pet) along with treatment of the specific target.

the investigators decided to use fractionated whole brain radiation doses of 1.8 gy x 5 and 1.8 gy x 3. subjects will be followed with neurocognitive testing at 6 months post radiotherapy. subjects 1-5 - 9gy in 5 daily fractions subjects 6-10 - 5.4gy in 3 daily fractions

Eligibility criteria:
inclusion criteria: * clinical diagnosis of mild or moderate alzheimer's disease. * amyloid pet scan positivity. * korean mini-mental state examination score ≥10 and ≤24. * clinical dementia rating scale 0.5, 1 or 2. * ability to undergo neurocognitive assessment at baseline visit, alone or accomparined by a caregiver. * ability to understand the clinical trial and give an informed consent exclusion criteria: * previous therapeutic whole brain irradiation * evidence of seizure activity * evidence of active dermatological skin disease of the scalp. * history of malignant tumors. * pregnant or breastfeeding. * if the researcher determines that participation in this study is inadequate because of other findings that are considered clinically important.

Keywords: radiotherapy
trust-2: safety and efficacy of intravenous remodulin® in patients in india with pulmonary arterial hypertension (pah)

Conditions: Pulmonary Arterial Hypertension

Summary: this was an open-label extension of study riv-ph-402, trust-1: treprostinil for untreated symptomatic pulmonary arterial hypertension (pah) trial. subjects who completed study riv-ph-402 were eligible to enroll.


Eligibility criteria:
inclusion criteria: * subjects who were enrolled in and completed study riv-ph-402 (trust-1) exclusion criteria: * subjects who were unblinded for potential rescue therapy in study riv-ph-402 and were found to be allocated to the remodulin treatment group were not eligible to participate in this study.

Keywords: remodulin 6-minute walk test